Prognostic markers for metastatic colon cancer patients undergoing multiple metastasectomies COLON

Özet

ABSTRACT Background/Aims: Following metastasis resection, 5-year survival rate has been reported as approximately 40%. There is no consensus regarding prognostic factors related to progression-free survival after repeated metastasec- tomies. Materials and Methods: A total of 21 patients with metastatic colorectal cancer who underwent repeated metasta- sectomies were retrospectively analyzed. The periods between the first and second metastasectomies and that be- tween the second metastasectomy and progression were defined as metastasis-free survival 1 (MFS1) and metastasis- free survival 2 (MFS2), respectively. Univariate analysis was used to analyze factors related to MFS1 and MFS2. Results: Approximately two-thirds of the patients had synchronous metastasis, which were localized mostly in the liver (90%). During a 49-months follow-up, MFS1 was 15.7 (8.4 23) months and MFS2 was 26.3 (12.3 40.4) months. Systemic chemotherapy followed the first metastasectomy (p=0.01), and the recurrence site (p=0.03) was found to be related to MFS1. Furthermore, the number of metastases during the first metastasectomy (p=0.02), the type of the chemotherapy regimen administered following the first metastasectomy (p=0.04), and the number of metas- tases before the second metastasectomy (p=0.03) were significantly related to MFS2. Conclusion: Surgical resection is currently the most effective and curative form of therapy for colorectal metastasis, whenever possible. Repeated metastasectomies can be achieved safely in experienced centers; thus, the operabil- ity of the patients should be evaluated by a multidisciplinary approach during treatment.